134892-45-8

Basic information

• Product Name: 6-AMINOCHINOXALIN-5-BROMCHINOXALIN
• CAS NO: 134892-45-8
• Molecular Formula: C8H6BrN3
• Molecular Weight: 224.05734
• Mol File: 134892-45-8.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-AMINOCHINOXALIN-5-BROMCHINOXALIN(CAS DataBase Reference)
• NIST Chemistry Reference: 6-AMINOCHINOXALIN-5-BROMCHINOXALIN(134892-45-8)
• EPA Substance Registry System: 6-AMINOCHINOXALIN-5-BROMCHINOXALIN(134892-45-8)

Safety Data

• Hazardous Substances Data: 134892-45-8(Hazardous Substances Data)

Upstream product

• 6298-37-9 6-aminoquinoxaline 

Downstream Products

• 59803-98-4 5-bromo-6-(imidazolin-2-ylamino)-quinoxaline 
• 1400635-36-0 (5-bromoquinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine L-tartrate 

Relevant articles and documents

Methods of preventing and reducing the severity of stress-associated conditions

The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatogical conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.

METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES

A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: STR1 and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R 1 and R 2 each is independently selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7-or 8-positions of the quinoxaline nucleus, and R 3, R 4 and R 5 each is located in one of the remaining 5-, 6-, 7-or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide treatment for ischemia.

METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES

A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: STR1 ,pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R 1 and R 4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R 2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R 3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7-or 8-positions of the quinoxaline nucleus; and R 5, R 6 and R 7 each is located in one of the remaining 5-, 6-, 7-or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain, anesthetization of the central nervous system, constriction of one or more blood vessels, reduction in or prevention of at least one effect of ischemia, decongestion of one or more nasal passages, and reduction of at least one effect of an inflammatory disorder.